InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
7
T+90 hit rate
50%
T+90 mean return
+0.5%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Kassberg Thomas Richard, Directeur Commercial et EVP. Director active across 1 company, notably Ultragenyx Pharmaceutical Inc.. Cumulatively, 13 disclosures have been recorded. Split: 0 buy · 7 sells. Total volume traded: €1.4m. Activity tracked since 6 May 2021. The latest transaction was filed on 1 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations13 total
18,443 shares0Common StockSEC:0000950170-25-032802:0
11,509 shares@ US$49.9330.6% of flowCommon StockSEC:0000950170-24-029780:0
17,800 shares0Common StockSEC:0000950170-24-026661:0
39,878 shares@ US$6.8614.9% of flowCommon StockSEC:0001209191-23-053487:0
2,663 shares0Common StockSEC:0001209191-23-016046:0
10,281 shares@ US$67.010.025% mcap67.0% of flowCommon StockSEC:0001209191-22-018829:0
2,374 shares@ US$66.620.0057% mcap15.1% of flowCommon StockSEC:0001209191-22-015806:0
286 shares@ US$81.141.2% of flowCommon StockSEC:0001209191-21-060754
286 shares@ US$81.140.0008% mcap2.1% of flowCommon StockSEC:0001209191-21-060754:0
109,734 shares@ US$0.310.0012% mcap3.1% of flowCommon StockSEC:0001209191-21-058365:0
109,734 shares@ US$0.311.7% of flowCommon StockSEC:0001209191-21-058365
363 shares@ US$113.693.7% of flowCommon StockSEC:0001209191-21-031384
363 shares@ US$113.690.0014% mcap3.7% of flowCommon StockSEC:0001209191-21-031384:0
13 of 13 declarations
About Kassberg Thomas Richard
Thomas Richard Kassberg serves as Chief Business Officer and EVP at Ultragenyx Pharmaceutical Inc. In this role, he is responsible for the company's business strategy and growth. Kassberg plays a key role in developing partnerships and expanding markets for Ultragenyx, a biopharmaceutical company specializing in treatments for rare diseases. His expertise in business development is essential for achieving the company's strategic objectives.
